GlassScriptPhysician profile
Donna S Waters
NPI 1306864061
$3,137.77
in general payments reported to CMS, 2019-2025
40 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $326 · 2021: $40.04 · 2022: $343 · 2023: $580 · 2024: $279 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $712.58 | 2019-2025 | |
| Amgen INC. | $431.88 | 2019-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $291.04 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $204.54 | 2023-2025 | Myfembree |
| Pfizer INC. | $201.38 | 2019-2024 | |
| Millicent US INC | $139.29 | 2019-2024 | Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $115.83 | 2019-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $108.05 | 2023-2025 | Jemperli, Zejula |
| Therapeuticsmd, INC. | $70.34 | 2019-2022 | |
| Myovant Sciences INC. | $68.76 | 2022 | |
| Scynexis, INC. | $62.03 | 2022 | |
| Mayne Pharma Commercial LLC | $60.63 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.77 | 2020-2025 | |
| Pacira Pharmaceuticals Incorporated | $46.08 | 2023-2025 | Exparel |
| Takeda Pharmaceuticals U.S.A., INC. | $45.40 | 2019 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $43.37 | 2022-2023 | Nexplanon |
| Hologic Sales and Service, LLC | $37.25 | 2019-2022 | |
| Clovis Oncology, INC. | $29.25 | 2019-2020 | |
| Caris Mpi, INC. | $27.92 | 2025 | Mi Cancer Seek |
| Avion Pharmaceuticals | $25.02 | 2022 | |
| Pharmaand Gmbh | $24.97 | 2025 | Rubraca |
| Astrazeneca Pharmaceuticals LP | $24.22 | 2024 | Enhertu |
| Davol INC. | $23.99 | 2023 | Arista Ah Flexitip |
| Shield Therapeutics INC | $23.21 | 2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $22.10 | 2019 | |
| Myriad Genetic Laboratories, INC. | $22.04 | 2021 | |
| Becton, Dickinson and Company | $21.41 | 2022 | |
| Convatec INC. | $21.01 | 2019 | |
| Teleflex LLC | $20.46 | 2019 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Coopersurgical, INC. | $17.31 | 2025 | Ally II Ups |
| Exeltis, USA INC. | $16.41 | 2019 | |
| Allergan, INC. | $15.37 | 2019 | |
| Medtronic, INC. | $15.14 | 2022 | |
| Duchesnay USA Incorporated | $15.10 | 2019 | |
| Radius Health, INC. | $14.44 | 2019 | |
| Urovant Sciences INC | $13.78 | 2022 | |
| Lupin INC. | $13.74 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.34 | 2019 | |
| Meditrina | $11.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.